Literature DB >> 9855326

Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6-beta-hydroxycortisol:cortisol ratios.

A H Burstein1, W G Reiss, E Kantor, G D Anderson.   

Abstract

STUDY
OBJECTIVE: To characterize cytochrome P450 (CYP) 3A4 activity in premenopausal and postmenopausal women by evaluating the urinary 6-beta-hydroxycortisol:cortisol ratio.
DESIGN: Prospective study
SUBJECTS: Thirteen premenopausal and 13 postmenopausal women who were healthy and not receiving drugs known to affect CYP3A4 activity
INTERVENTIONS: Beginning on day 2 of menses, premenopausal women collected first morning urine samples every other day for a complete menstrual cycle. Postmenopausal women collected first morning urine every other day for 28 days.
MEASUREMENTS AND MAIN RESULTS: Mean weekly 6-beta-hydroxycortisol:cortisol ratios did not differ during the phase (week) of the menstrual cycle. Daily ratios did not differ in postmenopausal women. No difference between premenopausal and postmenopausal women was found on comparing overall median ratios.
CONCLUSION: Cytochrome P450 3A4 activity as measured by 6-beta-hydroxy cortisol:cortisol ratio did not differ by week of menstrual cycle, suggesting no menstrual cycle-related changes. Menopause does not appear to be associated with differences in CYP3A4 activity, compared with premenopause.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855326

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  7 in total

Review 1.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.

Authors:  E J Reschly; Matthew D Krasowski
Journal:  Curr Drug Metab       Date:  2006-05       Impact factor: 3.731

2.  Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.

Authors:  Ya-Chi Chen; S Karl Gotzkowsky; Anne N Nafziger; Robert W Kulawy; Mario L Rocci; Joseph S Bertino; Angela D M Kashuba
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

Review 3.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

Review 4.  Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence.

Authors:  Mj Kennedy
Journal:  Clin Pharmacol Ther       Date:  2008-10-29       Impact factor: 6.875

5.  In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.

Authors:  Melanie S Joy; Reginald F Frye; Thomas D Nolin; Brittney V Roberts; Mary K La; Jinzhao Wang; Kim L R Brouwer; Mary Anne Dooley; Ronald J Falk
Journal:  Pharmacotherapy       Date:  2013-09-06       Impact factor: 4.705

6.  Studies on CYP3A activity during the menstrual cycle as measured by urinary 6β-hydroxycortisol/cortisol.

Authors:  Helena Bergström; Anna Lindahl; Anna Warnqvist; Ulf Diczfalusy; Lena Ekström; Linda Björkhem-Bergman
Journal:  Pharmacol Res Perspect       Date:  2021-12

7.  Changes in saccharin preference behavior as a primary outcome to evaluate pain and analgesia in acetic acid-induced visceral pain in mice.

Authors:  Beatriz de la Puente; Elizabeth Romero-Alejo; José Miguel Vela; Manuel Merlos; Daniel Zamanillo; Enrique Portillo-Salido
Journal:  J Pain Res       Date:  2015-10-06       Impact factor: 3.133

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.